Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114990 | 0.88 | BRAF (0.49) | BRAFHRH3CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL5204518 | 0.84 | BRAF (0.65) | BRAFHRH3CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL5106246 | 0.84 | BRAF (0.51) | BRAFHRH3CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL5109890 | 0.82 | BRAF (0.47) | BRAFHRH3CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL5103170 | 0.80 | BRAF (0.47) | BRAFHRH3 | |
| SCHEMBL5118285 | 0.78 | BRAF (0.59) | BRAFCYP1A2CYP11B1CYP11B2 | |
| SCHEMBL5111565 | 0.77 | BRAF (0.45) | BRAF | |
| SCHEMBL14038826 | 0.77 | BRAF (0.51) | BRAFHRH3 | |
| SCHEMBL5109313 | 0.77 | BRAF (0.72) | BRAFCYP1A2CYP11B1CYP11B2 | |
| SCHEMBL14038760 | 0.77 | BRAF (0.49) | BRAFHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452906-B2 | Pyridine derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-11-18 | — | — | US | disclosed |
| EP-1423384-B1 | PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2007-05-23 | — | — | EP | disclosed |
| US-20040235843-A1 | Pyridine derivatives as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-11-25 | — | — | US | disclosed |
| EP-1423384-A1 | PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003022840-A1 | PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235843-A1 | Pyridine derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885HRH3 658/4885CYP1A2 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.